bluebird bio Reports Third Quarter 2024 Results and Highlights Operational Progress and 2024 Guidance
bluebird bio, Inc. (BLUE)
Last bluebird bio, inc. earnings: 2/18 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.bluebirdbio.com/investor-overview
Company Research
Source: Business Wire
- 74 patient starts completed or scheduled to date in 2024 across bluebird’s commercial portfolio -- Third quarter 2024 net revenue of $10.6 million reflects quarter-to-quarter fluctuations in drug product infusions; anticipate at least $25 million of net revenue in the fourth quarter -- Management to host conference call today, November 14, 2024 at 8:00 am ET - SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird bio” or the “Company”) today reported third quarter results and business highlights for the quarter ended September 30, 2024, including recent commercial and operational progress.“Patient starts more than doubled from our second to third quarter update, providing clear evidence that our commercial launches continued to accelerate,” said Andrew Obenshain, chief executive officer. “This momentum, coupled with steps we took in the third quarter to increase manufacturing capacity for ZYNTEGLO and optimize our cost structure, is propelling bluebird
Show less
Read more
Impact Snapshot
Event Time:
BLUE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BLUE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BLUE alerts
High impacting bluebird bio, Inc. news events
Weekly update
A roundup of the hottest topics
BLUE
News
- bluebird bio, Inc. (NASDAQ: BLUE) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- bluebird bio, Inc. (NASDAQ: BLUE) had its "sector perform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $4.00 price target on the stock.MarketBeat
- bluebird bio, Inc. (NASDAQ: BLUE) had its price target lowered by analysts at Barclays PLC from $4.00 to $2.00. They now have an "overweight" rating on the stock.MarketBeat
- bluebird bio, Inc. (NASDAQ: BLUE) was downgraded by analysts at JPMorgan Chase & Co. from a "neutral" rating to an "underweight" rating.MarketBeat
- bluebird bio, Inc. (NASDAQ: BLUE) was downgraded by analysts at Bank of America Co. from a "buy" rating to a "neutral" rating. They now have a $0.50 price target on the stock, down previously from $3.00.MarketBeat
BLUE
Earnings
- 11/14/24 - Beat
BLUE
Sec Filings
- 11/14/24 - Form DEFA14A
- 11/14/24 - Form SC
- 11/14/24 - Form S-8
- BLUE's page on the SEC website